Core Insights - Tesla's stock has recently experienced volatility, with significant resistance observed at the $359 level, indicating a pattern of buyer's remorse [1][2] - The stock has found support around the $285 level, which was previously a support level in early June, demonstrating seller's remorse [4][6] Group 1: Resistance Levels - Resistance at $359 was created by remorseful buyers who sold their shares to break even after initially purchasing at that price [2][4] - This resistance has been observed multiple times throughout the year, indicating a recurring pattern in trading behavior [2][4] Group 2: Support Levels - Support at $285 formed due to remorseful sellers who regretted selling their shares when the price rallied back [5][6] - The stock's ability to find support at previously established levels highlights the psychological factors influencing trading decisions [5][6] Group 3: Trading Lessons - The trading patterns of Tesla illustrate the concepts of buyer's remorse leading to resistance and seller's remorse leading to support [7] - Understanding these psychological factors can aid traders in making informed decisions and identifying potential profit opportunities [7]

$40-$42 main resistance on hype$109k-$112k main resistance on bitcoinboth good spots to hedge spot bags until confirmed breakout higherbelieve both will be at ATHs in Q4Ansem (@blknoiz06):Q3want to buy bitcoin $88k-$91k for swing to $150k+want to buy hyperliquid $27-31 for swing to XXX ...

Group 1 - Bank of America Corporation (BAC) is experiencing a bullish trend, with shares trading higher and potentially breaking out, indicating a continued upward movement in stock price [1] - The current market conditions, with many stocks reaching all-time highs, contribute to the breakout of Bank of America shares [1] - A stock in an uptrend suggests an imbalance in the market, where demand exceeds supply, leading to increased competition among buyers and driving prices up [2] Group 2 - Resistance levels in stock trading represent price points where selling interest is strong enough to meet buying demand, often causing price rallies to pause or reverse [4] - Anxious sellers may lower their asking prices to avoid being undercut, which can create a downward price spiral if many sellers act similarly [5] - Breakouts occur when buyers overpower sellers at resistance levels, leading to a potential new uptrend as supply diminishes and demand remains strong [6]

Core Points - Kane Biotech Inc. has completed the conversion of a $1 million unsecured demand loan from an insider into a 3% unsecured convertible debenture due on June 26, 2030 [1] - The closing of this transaction is subject to final approval from the TSX Venture Exchange [2] - At the Annual and Special Meeting of Shareholders, all resolutions were voted in favor with 98% or higher, including the election of three new board directors [3] Company Overview - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which contribute to antibiotic resistance in wounds, leading to serious clinical outcomes and high costs [4]

Core Viewpoint - BioVie Inc. is advancing its clinical-stage drug candidate bezisterim (NE3107) for the treatment of early Parkinson's disease, with a Phase 2 SUNRISE-PD trial set to present findings at an upcoming congress [1][2]. Company Overview - BioVie Inc. (NASDAQ: BIVI) focuses on developing innovative therapies for neurological disorders, including Alzheimer's disease, Parkinson's disease, and long COVID, as well as advanced liver disease [12]. - The company's lead candidate, bezisterim, is designed to modulate inflammation and enhance insulin sensitivity without immunosuppressive effects [7][12]. Clinical Trial Details - The SUNRISE-PD trial is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study lasting 20 weeks, allowing patients to participate either from home or at clinical sites [2][3]. - The trial aims to evaluate the safety and efficacy of bezisterim on both motor and non-motor symptoms in patients not previously treated with carbidopa/levodopa, with topline data expected in late 2025 or early 2026 [8]. Parkinson's Disease Context - Parkinson's disease is characterized by the loss of dopamine-producing neurons, leading to motor and non-motor symptoms that significantly impact quality of life [4]. - Traditional treatment with levodopa has limitations, including motor fluctuations and dyskinesia, highlighting the need for new therapeutic approaches [5]. Mechanism of Action - Bezisterim targets neuroinflammation and insulin resistance, which are implicated in the progression of Parkinson's disease, potentially offering a new treatment avenue [6][7]. Previous Research Findings - A prior Phase 2 study of bezisterim showed significant improvements in motor control and "morning on" symptoms when combined with levodopa, with no drug-related adverse events reported [9].

Pipeline Programs and Milestones - Nuvalent is advancing parallel lead programs for ROS1+ and ALK+ NSCLC in global clinical development, with potential for first FDA approval in 2026[4] - The company plans to report pivotal data for TKI pre-treated ROS1+ NSCLC from the ARROS-1 trial in 1H 2025 and complete rolling NDA submission in Q3 2025[14] - Topline pivotal data for TKI pre-treated ALK+ NSCLC from the ALKOVE-1 trial is anticipated by year-end 2025, with ALKAZAR Phase 3 trial for TKI-naïve ALK+ NSCLC planned to initiate in early 2H 2025[14, 205] - NVL-330 for HER2-altered NSCLC is in Phase 1a/1b investigation, with additional discovery research programs ongoing[12, 205] Zidesamtinib (NVL-520) for ROS1+ NSCLC - In TKI pre-treated ROS1+ NSCLC patients, the ORR was 44% (51/117), with 78% (95% CI: 62, 88) DOR ≥ 12 months and 62% (95% CI: 28, 84) DOR ≥ 18 months[73] - In patients with prior crizotinib or entrectinib only ± chemotherapy, the ORR was 51% (28/55), with 93% (95% CI: 74, 98) DOR ≥ 12 months and 93% (95% CI: 74, 98) DOR ≥ 18 months[80] - Zidesamtinib demonstrated CNS activity, with an IC-ORR of 48% (27/56) in any prior ROS1 TKI ± chemotherapy and 85% (11/13) in prior crizotinib only ± chemotherapy[90] - The safety profile of zidesamtinib was generally well-tolerated, with peripheral edema reported in 36% of patients, constipation in 17%, blood CPK increased in 16%, fatigue in 16%, and dyspnea in 15%[96] - In TKI-naïve patients with ROS1+ NSCLC, the ORR was 89% (31/35), with 96% (95% CI: 76, 99) DOR ≥ 6 months and 96% (95% CI: 76, 99) DOR ≥ 12 months[103] Neladalkib (NVL-655) for ALK+ NSCLC - In a heavily pre-treated ALK+ solid tumor population, 51% had any secondary ALK mutation, 26% had a compound ALK mutation, and 56% had a history of CNS metastasis[140, 141] - In all NSCLC response evaluable patients, across all doses, the ORR was 38% (39/103), with a mDOR of 144 months and 78% DOR > 6 months[149] - In patients with any ALK resistance mutation at RP2D, the ORR was 55% (12/22), with a mDOR not reached and 100% DOR > 6 months[158] - The preliminary safety profile of neladalkib was consistent with its ALK-selective design, with ALT increased in 34% of patients, AST increased in 30%, constipation in 16%, dysgeusia in 13%, and nausea in 12%[166] Market Overview - The combined worldwide sales for ALK and ROS1 TKIs in 2024 were approximately $31 billion[27]

Core Insights - Purple Biotech Ltd. presented new preclinical data on its CAPTN-3 tri-specific antibody platform at the EACR 2025, showcasing its potential to overcome tumor immune evasion and drug resistance [1][2] Group 1: CAPTN-3 Platform Overview - The CAPTN-3 platform enables the creation of tri-specific antibodies that activate both innate and adaptive immune systems, enhancing anti-tumor responses [2][6] - The lead product, IM1240, targets the 5T4 antigen and has shown robust in vivo anti-tumor activity, particularly in triple negative breast cancer models [7][10] - The design includes an anti-NKG2A arm that synergizes with the anti-CD3 arm, demonstrating significant cytotoxic effects against solid tumor cells [3][4][5] Group 2: Mechanism of Action - The CAPTN-3 platform features a conditional activation mechanism, where the CD3 arm is activated only in the tumor microenvironment, minimizing systemic effects [6][7] - The anti-NKG2A arm plays a crucial role in reinvigorating exhausted T cells, enhancing their ability to kill tumor cells [4][5] - The platform's design allows for a modular approach, enabling the development of various tribodies with different target combinations [7][10] Group 3: Clinical Implications - Preclinical data indicate that the CAPTN-3 platform can lead to sustained tumor regression in animal models, highlighting its therapeutic potential [5][7] - The platform's ability to engage both T cells and NK cells suggests a promising avenue for developing effective cancer therapies [6][10] - The company is advancing multiple candidates within its oncology pipeline, including CM24 and NT219, alongside CAPTN-3 [10]

Core Viewpoint - The stock of The Estée Lauder Companies Inc. is experiencing consolidation after a significant gain, encountering resistance at approximately $74.75, which may indicate a potential for further movement in the stock price [1][2]. Price Movement and Resistance - The stock gained over 10% on Monday before hitting resistance at $74.75, a level previously established in late February [1][3]. - The resistance at this price level is attributed to buyer's remorse from previous investors who sold their shares when the price dropped [5][7]. Market Dynamics - The presence of remorseful buyers at the resistance level indicates that if these sellers can be overpowered by new buyers, the stock may experience a rapid increase in price [6]. - The gap down from around $80.80 to $74.75 in January created a situation where there was no trading in between these prices, leading to fewer sellers if the stock returns to these levels [7][8]. Implications for Future Trading - If the stock can surpass the resistance level, it may lead to a scenario where buyers compete against each other, potentially driving the price higher [8].

Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance [6] - The company's oncology pipeline includes NT219, CM24, and CAPTN-3, with NT219 being a dual inhibitor targeting IRS1/2 and STAT3 [6][7] Clinical Study Initiation - A Phase 2 clinical study has been initiated to evaluate NT219 in combination with either pembrolizumab or cetuximab for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) [1][4] - The study is led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus and structured into two single-arm cohorts [3] Mechanism of Action - NT219 is designed to induce degradation of IRS1/2 and inhibit phosphorylation of STAT3, blocking their signaling pathways [2] - Previous Phase 1 studies showed safety and anti-tumor activity of NT219 in combination with cetuximab, with two partial responses and five patients with stable disease [4] Market Potential - The SCCHN treatment market is projected to reach $5 billion by 2030, highlighting the need for more effective treatments due to challenges like tumor heterogeneity and therapeutic resistance [5]

Super Micro Computer TodaySMCISuper Micro Computer$43.36 +0.15 (+0.35%) 52-Week Range$17.25▼$101.40P/E Ratio21.77Price Target$45.63Add to WatchlistStudying the chart to look at levels of entry and exit is not enough in today’s market; investors need to understand the story behind each candlestick, each day, and each “pattern.” Today, more than ever, the stories behind these formations have to do with liquidity; since there are many more market participants than in recent periods, the so-called “smart money ...